Pharma Platform Phil Secures $25 Million in Series B Funding
Phil Inc., an end-to-end technology platform for distributing and managing specialty prescription drugs, closed a Series B $25 million funding round led by new investor GreatPoint Ventures, with support from Tarsadia Investments, Crosslink Capital, and Uncork Capital.
Specialty medications treat complex conditions such as rheumatoid arthritis and HIV. Phil, a San Francisco-based prescription management software platform, strives to offer a holistic approach and is founded on the principle that, while consistent access to recurring medications is a major user-experience issue, it cannot be solved with just a quick fix to any one point within the system.
Phil has earmarked the funding to fuel company growth, with a focus on hiring technical talent and expanding its geographic footprint.